Treating Acute Leukemias
in Europe

Bridging Science and Practice: From Newest Clinical Approaches to Real-World Clinical Cases

Register Now

Overview

This 2-day virtual program offers a comprehensive overview of the latest clinical updates and novel treatment strategies for acute leukemia, presented by experts. Attendees will have the opportunity to gain knowledge on optimal treatment of patients with leukemia, join patient case-based discussions, and interact with experts.

Register Now

Date and Location

September 18-19, 2025

Chair

Elias Jabbour

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

Naval Daver

Naval Daver, MD

MD Anderson Cancer Center, Houston, TX, USA

Faculty

Nicolas Boissel

Nicolas Boissel, MD

Saint-Louis Hospital, Paris, France

Nicola Gokbuget

Nicola Gökbuget, MD

University Hospital Frankfurt, Germany

José Maria Ribera

Josep-Maria Ribera, MD, PhD

Catalan Institute of Oncology, Badalona, Spain

Agenda

This 2-day interactive virtual meeting with global experts will focus on the treatment of patients with acute leukemia in various countries within Europe.

Day 1: Follow interactive presentations and case-based discussions with your peers on the latest updates for first-line assessments and treatments for adults and young adults with ALL, including the role of MRD, risk stratification, and tolerability and feasibility considerations. Engage with the faculty in panel discussions on optimal treatment and how first-line therapy will influence subsequent treatment options. Discuss regional case studies in newly diagnosed ALL with colleagues across Europe.

Day 2: Join to learn more about current state-of-the-art approaches for relapsed/refractory (R/R) ALL, and the evolving role of transplantation in Europe. Discuss regional case studies in R/R ALL with colleagues and discuss challenges with treating elderly and/or frail patients. Interact with faculty during a panel discussion on patient access and regional challenges across Europe.

Day 1: Virtual Plenary Sessions
Thursday, September 18, 2025 
18.00 – 21.00 UTC +2 (Central European Time)

Time (UTC +1) Topic Presenter
18.00 – 18.10 Welcome and meeting overview; introduction to the voting system Elias Jabbour
18.10 – 18.35 Latest achievements and developments in ALL Elias Jabbour
18.35 – 18.55 Review of prognostic and predictive markers in ALL Josep-Maria Ribera
18.55 – 19.25 Best practices for first-line treatment in ALL (including Ph+) Elias Jabbour
19.25 – 19.40 AYA patients with ALL: What is the current treatment approach for this diverse patient population? Special considerations for adolescents and young adults and how we can use this experience in adult patients Nicolas Boissel
19.40 – 19.50 Break  
19.50 – 20.25

ALL case-based panel discussion for first-line therapy

  • Case ALL: Adult high risk
    (Dr Gökbuget)
  • Case ALL: AYA (Dr Boissel)
 Panelists: All faculty
20.25 – 20.50

Panel discussion: How treatment in first line influences further therapy approaches in ALL

  • Role of HSCT – is it still necessary?
  • Have CAR Ts and bispecifics changed the treatment landscape? If so, how?
  • What does the future look like? Adoption of therapies and evolving standards of care in Europe
 (Moderated by Nicola Gökbuget)
Led by Elias Jabbour and all faculty
20.50 – 21.00 Session close Elias Jabbour

Day 2: Virtual Plenary Sessions
Friday, September 19, 2025
18.00 – 21.00 UTC +2 (Central European Time)

Time (UTC +2) Topic Presenter
18.00 – 18.10 Welcome to Day 2 Elias Jabbour
18.10 – 18.40 Current treatment options for relapsed/refractory (R/R) ALL in fit adults Elias Jabbour
18.40 – 19.00 Current treatment options for R/R ALL in elderly and frail patients Josep-Maria Ribera
19.00 – 19.20 Current and future role of transplantation in ALL in Europe Nicola Gökbuget
19.20 – 19.30 Break  
19.30 – 20.00 ALL case-based panel discussion for R/R ALL

  • Case ALL: Young (Dr Ribera)
  • Case ALL: Elderly (Dr Gökbuget)
 All faculty
20.00 – 20.20 Long-term safety considerations for ALL Nicolas Boissel
20.20 – 20.50

Panel discussion: Open questions in ALL – regional challenges (transplant, CAR T studies, and other)

  • Who are the ideal patients for CAR T therapy, bispecifics, and transplants in your practice?
  • What would be needed to make CAR T therapy available to all of your patients?
  • What would be needed to best position bispecifics in the continuum of care for ALL in adults?
  • How should transplant be best strategically combined with the new therapy modalities?

(Moderated by Nicolas Boissel)

Led by Elias Jabbour and all faculty
20.50 – 21.00 Session close Elias Jabbour

Register Now